CN101049504A - 一种脂质体药物载体及其制备方法 - Google Patents
一种脂质体药物载体及其制备方法 Download PDFInfo
- Publication number
- CN101049504A CN101049504A CNA2007100274247A CN200710027424A CN101049504A CN 101049504 A CN101049504 A CN 101049504A CN A2007100274247 A CNA2007100274247 A CN A2007100274247A CN 200710027424 A CN200710027424 A CN 200710027424A CN 101049504 A CN101049504 A CN 101049504A
- Authority
- CN
- China
- Prior art keywords
- liposome
- acid esters
- dibasic acid
- polyethylene glycol
- drug carrier
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002502 liposome Substances 0.000 title claims abstract description 177
- 238000002360 preparation method Methods 0.000 title claims description 11
- 239000003814 drug Substances 0.000 title abstract description 36
- 229940079593 drug Drugs 0.000 title description 9
- 229910019142 PO4 Inorganic materials 0.000 claims abstract description 45
- 239000010452 phosphate Substances 0.000 claims abstract description 45
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims abstract description 29
- 150000001413 amino acids Chemical class 0.000 claims abstract description 23
- 230000003064 anti-oxidating effect Effects 0.000 claims abstract description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 126
- 150000002148 esters Chemical class 0.000 claims description 57
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 48
- 229960003511 macrogol Drugs 0.000 claims description 45
- 239000002253 acid Substances 0.000 claims description 43
- -1 phosphate ester Chemical class 0.000 claims description 40
- 239000002202 Polyethylene glycol Substances 0.000 claims description 37
- 229920001223 polyethylene glycol Polymers 0.000 claims description 37
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 28
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 28
- 235000001014 amino acid Nutrition 0.000 claims description 22
- 238000003756 stirring Methods 0.000 claims description 22
- 239000003937 drug carrier Substances 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 19
- 239000007864 aqueous solution Substances 0.000 claims description 16
- 239000000243 solution Substances 0.000 claims description 10
- 125000002252 acyl group Chemical group 0.000 claims description 8
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 6
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 6
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 6
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 6
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 6
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 6
- 235000018417 cysteine Nutrition 0.000 claims description 6
- 229930182817 methionine Natural products 0.000 claims description 6
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 6
- 229920006395 saturated elastomer Polymers 0.000 claims description 5
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims description 4
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 claims description 4
- 229940093430 polyethylene glycol 1500 Drugs 0.000 claims description 4
- 229940085675 polyethylene glycol 800 Drugs 0.000 claims description 3
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 11
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract description 5
- 230000008569 process Effects 0.000 abstract description 3
- 208000031888 Mycoses Diseases 0.000 abstract 1
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 68
- 150000002632 lipids Chemical class 0.000 description 46
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 34
- 229960001948 caffeine Drugs 0.000 description 34
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 34
- 230000002269 spontaneous effect Effects 0.000 description 22
- 230000015572 biosynthetic process Effects 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 150000003904 phospholipids Chemical class 0.000 description 13
- 238000012360 testing method Methods 0.000 description 11
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 10
- 239000004005 microsphere Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 125000005456 glyceride group Chemical group 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical class CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 8
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 7
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 239000010413 mother solution Substances 0.000 description 6
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 239000010408 film Substances 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 239000007791 liquid phase Substances 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 4
- 238000005538 encapsulation Methods 0.000 description 4
- 239000003925 fat Substances 0.000 description 4
- 210000003128 head Anatomy 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 230000035699 permeability Effects 0.000 description 4
- 238000000108 ultra-filtration Methods 0.000 description 4
- 108010036949 Cyclosporine Proteins 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 229960001265 ciclosporin Drugs 0.000 description 3
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 210000002706 plastid Anatomy 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 3
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 3
- 229930105110 Cyclosporin A Natural products 0.000 description 2
- 239000000232 Lipid Bilayer Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 239000000823 artificial membrane Substances 0.000 description 2
- 238000005452 bending Methods 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000009509 drug development Methods 0.000 description 2
- 238000000635 electron micrograph Methods 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- UHUSDOQQWJGJQS-UHFFFAOYSA-N glycerol 1,2-dioctadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(CO)OC(=O)CCCCCCCCCCCCCCCCC UHUSDOQQWJGJQS-UHFFFAOYSA-N 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- DUXYWXYOBMKGIN-UHFFFAOYSA-N trimyristin Chemical compound CCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCC DUXYWXYOBMKGIN-UHFFFAOYSA-N 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 206010011469 Crying Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003005 anticarcinogenic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000002390 cell membrane structure Anatomy 0.000 description 1
- IOJUPLGTWVMSFF-UHFFFAOYSA-N cyclobenzothiazole Natural products C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 150000002327 glycerophospholipids Chemical class 0.000 description 1
- KYYWBEYKBLQSFW-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCC(O)=O KYYWBEYKBLQSFW-UHFFFAOYSA-N 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000004531 microgranule Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- UORPHRRDLIGMDN-SVMKZPJVSA-N octadec-2-enoic acid;(z)-octadec-9-enoic acid Chemical compound CCCCCCCCCCCCCCCC=CC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O UORPHRRDLIGMDN-SVMKZPJVSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 150000002885 octadecanoids Chemical class 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- ZTUXEFFFLOVXQE-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCC(O)=O ZTUXEFFFLOVXQE-UHFFFAOYSA-N 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
脂质分子 | 是否自动形成脂质体 | ||
20℃ | 37℃ | 50℃ | |
聚乙二醇200双油酸甘油酯 | 是 | 是 | 是 |
聚乙二醇400双油酸甘油酯 | 是 | 是 | 是 |
聚乙二醇600双油酸甘油酯 | 是 | 是 | 是 |
聚乙二醇800双油酸甘油酯 | 否 | 是 | 是 |
聚乙二醇1500双油酸甘油酯 | 否 | 否 | 是 |
脂质分子 | 是否自动形成脂质体 | ||
20℃ | 37℃ | 50℃ | |
聚乙二醇600双硬脂酸甘油酯 | 否 | 否 | 是 |
聚乙二醇600双软脂酸甘油酯 | 是 | 是 | 是 |
聚乙二醇600双肉豆蔻酸甘油酯 | 是 | 是 | 是 |
聚乙二醇600双月桂酸甘油酯 | 是 | 是 | 是 |
聚乙二醇600-1-硬脂酸-2-油酸甘油酯 | 否 | 是 | 是 |
聚乙二醇600-1-软脂酸-2-油酸甘油酯 | 是 | 是 | 是 |
聚乙二醇600-1-肉豆蔻酸-2-油酸甘油酯 | 是 | 是 | 是 |
聚乙二醇600-1-月桂酸-2-油酸甘油酯 | 是 | 是 | 是 |
聚乙二醇800双油酸甘油酯浓度% | 磷脂POPC浓度% | 是否自动形成脂质体 | ||
20℃ | 37℃ | 50℃ | ||
95 | 5 | 是 | 是 | 是 |
90 | 10 | 是 | 是 | 是 |
85 | 15 | 是 | 是 | 是 |
80 | 20 | 是 | 是 | 是 |
70 | 30 | 否 | 否 | 是 |
50 | 50 | 否 | 否 | 否 |
成分 | 最终浓度 |
聚乙二醇600双油酸甘油酯 | 5% |
磷酸酯POPC | 1% |
环孢霉素A | 1% |
海藻糖 | 1% |
氨基酸溶液母液 | 50mM |
水 | 加至100% |
成分 | 最终浓度 |
聚乙二醇600双油酸甘油酯 | 5% |
磷酸酯POPC | 1% |
AMPB | 0.5% |
海藻糖 | 1% |
氨基酸溶液母液 | 50mM |
水 | 加至100% |
Claims (10)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200710027424A CN101049504B (zh) | 2007-04-05 | 2007-04-05 | 一种脂质体药物载体及其制备方法 |
PCT/CN2008/000511 WO2008122192A1 (fr) | 2007-04-05 | 2008-03-14 | Véhicule pharmaceutique liposomal et son procédé de préparation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200710027424A CN101049504B (zh) | 2007-04-05 | 2007-04-05 | 一种脂质体药物载体及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101049504A true CN101049504A (zh) | 2007-10-10 |
CN101049504B CN101049504B (zh) | 2010-05-19 |
Family
ID=38781239
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200710027424A Active CN101049504B (zh) | 2007-04-05 | 2007-04-05 | 一种脂质体药物载体及其制备方法 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN101049504B (zh) |
WO (1) | WO2008122192A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104758249A (zh) * | 2014-01-07 | 2015-07-08 | 南洋理工大学 | 用于眼药物递送的稳定的脂质体制剂 |
CN112958285A (zh) * | 2021-02-01 | 2021-06-15 | 核工业北京化工冶金研究院 | 一种用于贝塔石浮选的复配辅助捕收剂及其应用 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101587412B1 (ko) * | 2014-10-17 | 2016-01-21 | 주식회사 휴온스 | 사이클로스포린 및 트레할로스를 포함하는 안과용 조성물 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5858401A (en) * | 1996-01-22 | 1999-01-12 | Sidmak Laboratories, Inc. | Pharmaceutical composition for cyclosporines |
IT1289938B1 (it) * | 1997-02-20 | 1998-10-19 | Angelini Ricerche Spa | Preparazione farmaceutica comprendente liposomi liofilizzati in cui e' incapsulato un principio attivo altamente insolubile in acqua e |
WO2004069180A2 (en) * | 2003-01-31 | 2004-08-19 | Smithkline Beecham Corporation | Solid dispersion compositions |
-
2007
- 2007-04-05 CN CN200710027424A patent/CN101049504B/zh active Active
-
2008
- 2008-03-14 WO PCT/CN2008/000511 patent/WO2008122192A1/zh active Application Filing
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104758249A (zh) * | 2014-01-07 | 2015-07-08 | 南洋理工大学 | 用于眼药物递送的稳定的脂质体制剂 |
CN104758249B (zh) * | 2014-01-07 | 2019-08-23 | 南洋理工大学 | 用于眼药物递送的稳定的脂质体制剂 |
CN112958285A (zh) * | 2021-02-01 | 2021-06-15 | 核工业北京化工冶金研究院 | 一种用于贝塔石浮选的复配辅助捕收剂及其应用 |
CN112958285B (zh) * | 2021-02-01 | 2022-08-05 | 核工业北京化工冶金研究院 | 一种用于贝塔石浮选的复配辅助捕收剂及其应用 |
Also Published As
Publication number | Publication date |
---|---|
WO2008122192A1 (fr) | 2008-10-16 |
CN101049504B (zh) | 2010-05-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2014002131A (es) | Pre-concentrado lipidico de liberacion sostenida de una sustancia farmacologicamente activa y una composicion farmaceutica que comprende el mismo. | |
JP2012504107A (ja) | 親油性または両親媒性治療薬のナノエマルションへの封入 | |
CN104306333B (zh) | 一种卡巴他赛脂质微球注射液及其制备方法 | |
CN101002733A (zh) | 一种稳定的脂质体组合物 | |
CN102302447A (zh) | 一种新型紫杉醇脂质微球注射液及其制备方法 | |
CN107837229A (zh) | 一种缓释阿霉素脂质体的温敏水凝胶制剂及制备方法 | |
CN101049504B (zh) | 一种脂质体药物载体及其制备方法 | |
CN103735504B (zh) | 一种伊立替康纳米脂束制剂及其制备方法 | |
CN113384705A (zh) | 泊洛沙姆修饰的脂质体的制备及在口服药物递送中的应用 | |
CN100350912C (zh) | 一种新型的聚乙二醇衍生化磷脂包载前列腺素e1的纳米微粒给药系统 | |
Zheng et al. | Carboxymethyl chitosan coated medium-chain fatty acid nanoliposomes: Structure, composition, stability and in vitro release investigation | |
CN1686106A (zh) | 冬凌草甲素微粒给药制剂及其制备方法 | |
US20230372442A1 (en) | Formulated and/or Co-Formulated Liposome Compositions Containing Toll-like Receptor("TLR") Agonist Prodrugs Useful In The Treatment of Cancer and Methods Thereof | |
CN102058530A (zh) | 一种灵芝多糖口服纳米乳剂及其制备方法 | |
US20230226031A1 (en) | Formulated and/or Co-Formulated Liposome Compositions Containing Immunogenic Cell Death (ICD) Inducing Prodrugs Useful In The Treatment of Cancer and Methods Thereof | |
CN103784400B (zh) | 一种聚乙二醇化磷脂包载胰岛素的口服胶束制剂 | |
CN103054799B (zh) | 一种盐酸胺碘酮注射乳剂及其制备方法 | |
CN101822839B (zh) | 以海豹油为液相基质的纳米结构脂质载体的制备及应用 | |
US20210163418A1 (en) | Formulated and/or Co-Formulated Liposome Compositions Containing IDO Antagonist Prodrugs Useful In The Treatment of Cancer and Methods Thereof | |
CN107753433B (zh) | 一种纳米蛹虫草肽脂质体及其制备方法和一种口服液制剂 | |
CN101040847A (zh) | 一种采用氢化蓖麻油生产的纳米药物制剂及其制备工艺 | |
CN109336850A (zh) | 烷基醇修饰的多西他赛衍生物抗癌药物化合物及其制备方法和应用 | |
CN109381427A (zh) | 一种寡聚乙二醇修饰的多西他赛衍生物的注射剂 | |
CN109574960A (zh) | 一种多西他赛衍生物及其制备方法和应用 | |
US11833209B2 (en) | Formulated and/or co-formulated liposome compositions containing PD-1 antagonist prodrugs useful in the treatment of cancer and methods thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: ZHEJIANG GLLION BIOTECHNOLOGIES CO., LTD. Free format text: FORMER OWNER: LIEN BIOTECH CO., LTD., GUANGZHOU Effective date: 20120702 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 510730 GUANGZHOU, GUANGDONG PROVINCE TO: 314213 JIAXING, ZHEJIANG PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20120702 Address after: 314213 No. 1899, No. 1, Xingping, Zhejiang, Pinghu Patentee after: ZHEJIANG GLLION BIOSCIENCE Co.,Ltd. Address before: 505-507 room 13-15, No. two, Shawan 510730, Guangzhou economic and Technological Development Zone, Guangdong, China Patentee before: GUANGZHOU LI EN BIOTECHNOLOGIES Co.,Ltd. |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: The invention relates to a liposome drug carrier and a preparation method thereof Effective date of registration: 20211102 Granted publication date: 20100519 Pledgee: Pinghu Rural Commercial Bank of Zhejiang, Limited by Share Ltd. Pledgor: ZHEJIANG GLLION BIOSCIENCE Co.,Ltd. Registration number: Y2021330002136 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20230907 Granted publication date: 20100519 Pledgee: Pinghu Rural Commercial Bank of Zhejiang, Limited by Share Ltd. Pledgor: ZHEJIANG GLLION BIOSCIENCE Co.,Ltd. Registration number: Y2021330002136 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right |